Emmens CW, Cox RI, Martin L: Antiestrogens. Recent Prog Horm Res. 1962, 18: 415-466.
CAS
Google Scholar
Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. [see comments]. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.
Article
Google Scholar
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.
Article
CAS
PubMed
Google Scholar
United States Preventive Services Task Force: Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med. 2002, 137: 56-58.
Article
Google Scholar
The ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002, 359: 2131-2139. 10.1016/S0140-6736(02)09088-8.
Article
Google Scholar
Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981, 304: 16-21.
Article
CAS
PubMed
Google Scholar
Colletta AA, Benson JR, Baum M: Alternative mechanisms of action of antioestrogens. Breast Cancer Res Treat. 1994, 31: 5-9.
Article
CAS
PubMed
Google Scholar
Wishart GC, Gaston M, Poultsidis AA, Purushotham AD: Hormone receptor status in primary breast cancer – time for a consensus?. Eur J Cancer. 2002, 38: 1201-1203. 10.1016/S0959-8049(01)00304-5.
Article
CAS
PubMed
Google Scholar
Ellis MJ, Coop A, Singh B, Mauriac L, Llambert F, Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M: Letrozole is more effective neoadjuvant endocrine therapy then tamoxifen for ErbB-1 and/or ErbB-2 positive estrogen receptor positive primary breast cancer: evidence from a phase III study. J Clin Oncol. 2001, 19: 3808-3816.
CAS
PubMed
Google Scholar
Ravdin P: Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer [editorial]. Lancet. 2002, 359: 2126-2127. 10.1016/S0140-6736(02)09111-0.
Article
PubMed
Google Scholar
Jordan VC: Designer estrogens. Sci Am. 1998, 279: 60-67.
Article
CAS
PubMed
Google Scholar
Jordan VC: Selective estrogen receptor modulation: a personal perspective. Perspectives in Cancer Research. Cancer Res. 2001, 61: 5683-5687.
CAS
PubMed
Google Scholar
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999, 281: 2189-2197. 10.1001/jama.281.23.2189.
Article
CAS
PubMed
Google Scholar
Hershman D, Sundararajan V, Jacobson JS, Heitjan DF, Neugut AI, Grann VR: Outcomes of tamoxifen for breast cancer in very high risk women: a cost effectivness analysis. J Clin Oncol. 2002, 20: 9-16. 10.1200/JCO.20.1.9.
Article
CAS
PubMed
Google Scholar
Jordan VC, Morrow MM: Chemoprevention of breast cancer: a model for change. J Clin Oncol. 2002, 20: 1-2.
PubMed
Google Scholar
Jordan VC, Morrow M: Raloxifene as a multifunctional medicine?. BMJ. 1999, 319: 331-332.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lerner LJ, Jordan VC: The development of antiestrogens for the treatment of breast cancer. Cancer Res. 1990, 50: 4177-4189.
CAS
PubMed
Google Scholar
Jordan VC, Gapstur S, Morrow M: Selective estrogen receptor modulation to reduce breast cancer risk, osteoporosis and coronary heart disease. J Natl Cancer Inst. 2001, 93: 1449-1457. 10.1093/jnci/93.19.1449.
Article
CAS
PubMed
Google Scholar
Jordan VC: Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. J Med Chem. 2002,
Google Scholar